Assenagon Asset Management S.A. Cuts Holdings in Codexis, Inc. (NASDAQ:CDXS)

Assenagon Asset Management S.A. cut its holdings in Codexis, Inc. (NASDAQ:CDXSFree Report) by 73.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 287,864 shares of the biotechnology company’s stock after selling 815,578 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Codexis were worth $1,373,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in Codexis during the third quarter worth about $66,000. Marshall Wace LLP purchased a new stake in shares of Codexis during the 2nd quarter worth approximately $89,000. Algert Global LLC boosted its stake in shares of Codexis by 17.1% during the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 6,069 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Codexis by 113.8% in the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 39,664 shares during the period. Finally, GSA Capital Partners LLP increased its stake in Codexis by 83.5% in the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 45,337 shares in the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CDXS. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research note on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of Codexis in a research report on Friday, November 22nd.

Check Out Our Latest Report on CDXS

Codexis Stock Performance

Shares of CDXS opened at $4.98 on Friday. Codexis, Inc. has a 1 year low of $2.53 and a 1 year high of $6.08. The company’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $3.79. The company has a market capitalization of $405.27 million, a price-to-earnings ratio of -5.72 and a beta of 2.13. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21.

Codexis (NASDAQ:CDXSGet Free Report) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The company had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. On average, sell-side analysts predict that Codexis, Inc. will post -0.77 EPS for the current year.

Codexis Profile

(Free Report)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

Featured Articles

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXSFree Report).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.